EREG
EREG (Proepiregulin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Non-small-cell lung cancer.
Overview
Ligand of the EGF receptor/EGFR and ERBB4. Stimulates EGFR and ERBB4 tyrosine phosphorylation. Contributes to inflammation, wound healing, tissue repair, and oocyte maturation by regulating angiogenesis and vascular remodeling and by stimulating cell proliferation.
CIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Cetuximab and Panitumumab. Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.98, affected pathway 0.88, genetic association 0.00).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · EREG (Proepiregulin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Non-small-cell lung cancer.
- 1 · What it is
EREG (Proepiregulin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Non-small-cell lung cancer.
- 2 · What goes wrong in cancer
Ligand of the EGF receptor/EGFR and ERBB4. Stimulates EGFR and ERBB4 tyrosine phosphorylation.
- 3 · How drugs use it
No product in this corpus aims at EREG yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:3443 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O14944 (protein name, function text, keywords and locations (REST API)); CIViC gene EREG (3 evidence items, 0 assertions, 2 variants; diseases: Colorectal Cancer, Lung Adenocarcinoma (GraphQL API, CC0)); Open Targets ENSG00000124882 (association with cancer (MONDO_0004992) 0.64; (GraphQL API, CC0))
Biology
Ligand of the EGF receptor/EGFR and ERBB4. Stimulates EGFR and ERBB4 tyrosine phosphorylation. Contributes to inflammation, wound healing, tissue repair, and oocyte maturation by regulating angiogenesis and vascular remodeling and by stimulating cell proliferation. Location: Secreted, extracellular space; Cell membrane (UniProt). Locus 4q13.3 (HGNC).
- Colorectal cancer: CIViC evidence names this disease
- Non-small-cell lung cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 3 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"EREG" OR ABSTRACT:"EREG" OR TITLE:"epiregulin" OR ABSTRACT:"epiregulin" OR TITLE:"Proepiregulin" OR ABSTRACT:"Proepiregulin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EREG, not a curated reading list.